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AbstrACt
Introduction For patients with perihilar 
cholangiocarcinoma (CCA), surgery is the only treatment 
modality that can result in cure. Unfortunately, in the 
majority of these patients, the tumours are found to be 
unresectable at presentation due to either local invasive 
tumour growth or the presence of distant metastases. For 
patients with unresectable CCA, palliative chemotherapy 
is the standard treatment yielding an estimated median 
overall survival (OS) of 12–15.2 months. There is no 
evidence from randomised trials to support the use 
of stereotactic body radiation therapy (SBRT) for CCA. 
However, small and most often retrospective studies 
combining chemotherapy with SBRT have shown 
promising results with OS reaching up to 33–35 months.
Methods and analysis This study has been designed as 
a single-centre phase I feasibility trial and will investigate 
the addition of SBRT after standard chemotherapy in 
patients with unresectable perihilar CCA (T1-4 N0-1 M0). A 
total of six patients will be included. SBRT will be delivered 
in 15 fractions of 3–4.5 Gy (risk adapted). The primary 
objective of this study is to determine feasibility and 
toxicity. Secondary outcomes include local tumour control, 
progression-free survival (PFS), OS and quality of life. 
Length of follow-up will be 2 years. As an ancillary study, 
the personalised effects of radiotherapy will be measured 
in vitro, in patient-derived tumour and bile duct organoid 
cultures.
Ethics and dissemination Ethics approval for the 
STRONG trial has been granted by the Medical Ethics 
Committee of Erasmus MC Rotterdam, the Netherlands. 
It is estimated that all patients will be included between 
October 2017 and October 2018. The results of this study 
will be published in a peer-reviewed journal, and presented 
at national and international conferences.
trial registration number NCT03307538; Pre-results.
IntroduCtIon
Cholangiocarcinoma (CCA) is the second most 
common primary liver tumour worldwide.1 
CCA accounts for 3% of all gastrointestinal 
tumours.2 Of all CCA, approximately 50%–70% 
arise at the hilar plate of the biliary tree, and 
these tumours are being referred to as either 
perihilar CCA or Klatskin tumours.3 Resection 
is the only potential curative treatment for 
patients with perihilar CCA. Median overall 
survival (OS) ranges from 27 to 58 months 
among operated patients with negative resec-
tion margins.4 Unfortunately, the majority of 
patients present with unresectable disease at 
diagnosis.4 5 Selected patients are eligible for 
liver transplantation. Five-year survival rates for 
both margin-negative resection and neoadju-
vant therapy combined with liver transplanta-
tion are similar.4 
The standard treatment for patients with 
unresectable or metastatic perihilar CCA is 
chemotherapy that consists of eight courses of 
gemcitabine and cisplatin. The survival rates 
for inoperable patients who receive this chemo-
therapy regimen are poor: Valle et al reported 
in a prospective study (ABC-02 trial) a median 
OS of 11.7 months and a PFS of 8.0 months.6 
In a retrospective study, Eckmann et al showed 
strengths and limitations of this study
 ► A promising local treatment option will be stud-
ied for patients with unresectable perihilar 
cholangiocarcinoma.
 ► The fractionation scheme used in this trial makes it 
possible to deliver a relative high-radiation dose to 
the tumour and protect surrounding organs.
 ► Toxicity will be closely observed.
 ► Interfraction and intrafraction motion will be as-
sessed using multiple CT scans during treatment.
 ► The study population is small; therefore, no robust 
analysis other than feasibility and toxicity can be 
done.
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a median OS of 15.2 months in these patients treated 
with gemcitabine and cisplatin. Partial response or stable 
disease rates of 72% were found, with a median duration of 
response of 8.1 months.7
Local ablative therapies
Because of these poor OS rates for patients treated with 
chemotherapy, some local therapies have been investigated. 
One of these treatment options is ablation with irreversible 
electroporation (IRE), which is currently under investiga-
tion in the ALPACA trial.8 Until now there is little evidence 
to support the routine use of IRE for patients with perihilar 
CCA. One case report describes a technically successful 
procedure, but data on toxicity and disease outcome are 
lacking.9 Another local therapy option is radiofrequency 
ablation (RFA). Wu et al10 published a retrospective study 
that showed prolongation of stent patency and better 
functional status and quality of life (QoL) in a group of 
patients treated with intraductal RFA before stent place-
ment, compared with stent placement alone. There are no 
data on disease outcome after RFA. A third ablative therapy 
option is photodynamic therapy using temoporfin. Wagner 
et al report a local response after one treatment of 55%, with 
a median time to local tumour progression of 6.5 months, 
but also a high percentage of cutaneous photo toxicity 
(41%).11 Finally, brachytherapy has been studied mostly as 
a palliative treatment in combination with external beam 
radiotherapy or in a neoadjuvant setting. In combination 
with external beam radiotherapy, survival rates are poor, 
with a median OS of 12 months.12
stereotactic body radiation therapy
Also, the role for radiotherapy in the treatment of CCA is 
currently not well defined. Various groups have tried to 
use stereotactic body radiation therapy (SBRT) to deliver 
high-radiation doses to control the disease locally. Most of 
the published studies have been retrospective (table 1).
SBRT has been explored as single-modality treatment in 
patients who are unsuitable for resection, although it has 
also been administered as adjuvant treatment after surgery 
with positive margins.13 The patient groups were almost 
invariably small and/or heterogeneous, which makes it 
hard to draw firm conclusions.13–21 Most studies did not limit 
number or size of lesions, with the exception of one study 
(maximum diameter of ≥6 cm was an exclusion criterion).16
High rates of 2-year local control (LC) after SBRT have 
been reported. In most studies, this was achieved in ≥72% 
of the patients. Median OS ranged between 10 and 35.5 
months, with five studies reporting OS ≥15 months, and 
three reporting OS >24 months.13–21 Tao et al found a 
Table 1 Treatment outcomes of SBRT for CCA
Author Design Location
Lesion
no
Fraction
no
Total 
dose (Gy)
1-year local
control (%)
Median 
survival
(months) Toxicity*
Kopek et al14 R PH-CCA
IH-CCA
26
1
3 45 84 10.6 6 ulceration
3 stenosis
Tse et al15 P IH-CCA 10 6 28–48 65 15 2 liver enzymes
1 bowel obstruction
Polistina et al16 R PH-CCA 10 3 30 80† 35.5 1 ulceration
2 stenosis
Barney et al17 R IH-CCA
PH-CCA
EH-CCA
6
3
1
3–5 45–60 100 15.5 1 biliary stenosis
2 liver failure
Momm et al18 R PH-CCA 13 8–16 32–56 N.R. 33.5 1 nausea
5 cholangitis
Jung et al19 R IH-CCA
EH-CCA
33
25
1–5 15–60 85 10 2 ulceration
2 cholangitis
1 biliary stenosis
1 gastric perforation
Mahadevan et al13 R IH-CCA
PH-CCA
31
11
1–5 10–45 88 17 2 duodenal ulceration
1 cholangitis
1 liver abscess
Tao et al20 R IH-CCA 79 15–30 50.4–75 81 30 3 cholangitis
2 gastric bleeding
7 biliary stenosis
Sandler et al21 R IH-CCA
EH-CCA
6
25
5 40 78 15.7 2 duodenal obstruction
3 duodenal ulceration
*Early and late toxicity, grade 3 or more.
†At 6 months.
EH-CCA, extrahepatic cholangiocarcinoma; IH-CCA, intrahepatic cholangiocarcinoma; N.R., not reported; P, prospective; PH-CCA, perihilar 
cholangiocarcinoma; R, retrospective; SBRT, stereotactic body radiation therapy.
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significant improvement in LC when high-radiation doses 
were delivered. When biologically effective doses (BEDs) 
were >80.5 Gy, 3-year LC was achieved in 78% vs 45% with 
lower doses.20
One of the difficulties for an SBRT treatment in the peri-
hilar region is the proximity of organs at risk (OAR) like 
the common bile duct and duodenum. The hepatobiliary 
toxicity reported by other groups varied widely but was 
generally limited in most of the series. A slightly higher 
number of gastrointestinal toxicity has been reported, 
mainly duodenal obstruction and stenosis (table 1).13–21 
This toxicity could potentially be limited by the application 
of strict dose–volume constraints.
MEthods And AnALysIs
design
This study has been designed as a single-centre phase I 
feasibility trial. Six patients with unresectable perihilar 
CCA, who already received the standard treatment with 
systemic chemotherapy (cisplatin and gemcitabine), will be 
included.
The reason to design a feasibility study is that no data 
have been published about the delivery of SBRT in 15 
fractions of 3–4.5 Gy in patients with perihilar CCA after 
chemotherapy. Data have been reported on patients with 
intrahepatic CCA treated with 15 fractions of radiotherapy, 
although the chemotherapy regimen and the timing of 
administration before or after the local treatment varied 
largely.20 The possibility of delivering the standard treat-
ment without interferences due to potential toxicity caused 
by SBRT was the main reason to choose for an adjuvant 
approach instead of neoadjuvant or concomitant.
The trial follows the conventional ‘3+3’-design. First three 
patients will be included, after which the trial will tempo-
rarily be put on hold for 3 months. When two or three 
patients develop limiting toxicity (LT), the conclusion will 
be that the proposed risk-adapted radiotherapy protocol is 
not feasible and the trial will be ended. When 0 or 1 of 3 
patients develops LT, 3 additional patients will be included. 
LT will be defined as grade 4 or more hepatobiliary toxicity 
related to study procedures, or grade 3 or more gastroin-
testinal toxicity related to study procedures, occurring in 
the period up to 3 months after the last SBRT adminis-
tration. When 0 or 1 of these 6 patients develops LT, then 
the conclusion will be that the current risk-adapted radio-
therapy protocol is feasible, and should be considered for 
further research in this patient population (ie, in a phase 
II trial). Otherwise, if two or more patients have limiting 
toxicity, the conclusion will be that the current risk-adapted 
radiotherapy protocol is not feasible. The most important 
toxicities are listed in box 1.
study objectives
Primary study outcome
The primary objective of this study will be to determine 
feasibility and toxicity (according to the Common Toxicity 
Criteria for Adverse Events (CTCAE) V.4.03 grading system) 
of adding SBRT to standard chemotherapy, in patients with 
perihilar CCA ineligible for surgery.
Secondary study outcomes
 ► LC defined as time from inclusion to local radiolog-
ical progression. Definition of progression is based on 
response evaluation criteria in solid tumors (RECIST) 
1.1.22
 ► Progression-free survival defined as time from inclu-
sion until radiological progression. Definition of 
progression is based on RECIST.
 ► OS defined as time from inclusion until death from 
any cause.
 ► QoL assessed by means of the EuroQol (EQ)-5D-5L 
(measure of health outcome in general popula-
tion), and the European Organisation for Research 
and Treatment of Cancer (EORTC) QLQ-C30 (QoL 
specific for patients with cancer) with the supplemen-
tary module EORTC QLQ-BIL21 (specific for CCA 
and gallbladder cancer).
 ► Cellular radiosensitivity, as a side track of this study. The 
effects of radiotherapy will be measured in normal bile 
duct organoids23 and CCA cancer-derived organoids 
(Broutier et al tumour-derived organoid cultures model 
primary human liver cancer in vitro, article in press) 
obtained from cells of brush cytology obtained during 
endoscopic retrograde cholangiopancreatography 
(ERCP). The goal is to set up assays to measure genomic 
mutations, cell death/apoptosis, cellular senescence 
and proliferative capacity after ionising radiation treat-
ment ex vivo. In the future, these effects will be meas-
ured in organoids and will be correlated with tumour 
response on imaging (CT/MRI) in a large phase II trial. 
Prediction of response and toxicity before treatment 
will be the ultimately goal of this approach in the future.
study population
Six patients with unresectable perihilar CCA after comple-
tion of standard chemotherapy with cisplatin and gemcit-
abine will be enrolled in this study. In order to be eligible, 
a subject must be discussed in a multidisciplinary liver 
box 1 toxicity
Gastrointestinal disorders
 ► Duodenal or gastric obstruction/stenosis
 ► Duodenal or gastric perforation
 ► Duodenal or gastric ulcer
hepatobiliary disorders
 ► Bile duct stenosis
 ► Perforation bile duct
Infections and infestations
 ► Biliary tract infection
Toxicity will be determined based on symptoms, laboratory, imaging and 
endoscopic examinations. Limiting toxicity is defined as grade 4 or more 
hepatobiliary toxicity related to study procedures, or grade 3 or more 
gastrointestinal toxicity related to study procedures.
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tumour board and should meet all of the inclusion and 
exclusion criteria as listed in table 2. All types of biliary 
stents are accepted. The expected time to include the 
required patients for this trial will be 1 year.
study outline
The general outline of the study procedures is presented 
in figure 1.
Prestereotactic body radiation therapy
Chemotherapy is considered the standard treatment for 
unresectable perihilar CCA, and therefore will not be 
considered as study treatment in this trial. Cisplatin plus 
gemcitabine will be administered according to standard 
practice of the Erasmus MC Cancer Institute. Chemo-
therapy will be discontinued at 24 weeks (eight cycles) or 
earlier in case of disease progression, patient or clinician 
decision, or unacceptable toxic effects. Biliary obstruction 
per se is not considered to be disease progression in the 
absence of radiologically confirmed tumour progression, 
and treatment can be recommenced after further biliary 
stenting and normalisation of liver function.6 In case 
of unacceptable toxic effects and in absence of disease 
progression, the patient can proceed to SBRT without 
completing eight cycles of chemotherapy. In that case, no 
signs of progressive disease should have been observed on a 
chest/abdomen CT scan performed within 6 weeks before 
patient inclusion.
Stereotactic body radiation therapy
Treatment with SBRT will start preferably within 6 weeks 
after the last chemotherapy course. However, if due to 
toxicity or other medical or personal reasons the start of 
the treatment has to be postponed, the time to start can be 
expanded till a maximum of 12 weeks after the last course 
of chemotherapy.
We will use a risk-adapted dose prescription for delivering 
the highest possible dose to the tumour, using 15 fractions 
of 3–4, 5 Gy, while not exceeding widely accepted dose 
Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
 ► Patients diagnosed with perihilar CCA according to the 
criteria of the Mayo Clinic, Rochester25:
 – Positive or strongly suspicious intraluminal brush or 
biopsy
 – A radiographic malignant appearing stricture plus either:
 – CA 19–9 >100 U/mL in the absence of acute bacterial 
cholangitis
 – Polysomy on FISH
 – A well-defined mass on cross-sectional imaging
 ► One tumour mass
 ► Unresectable tumour
 ► Finished chemotherapy treatment with gemcitabine and 
cisplatin, preferably eight cycles.* T1–T4 (AJCC staging 
seventh edition)† before chemotherapy
 ► N0–N1 (AJCC staging seventh edition), radiologically or 
pathologically suspect
 ► Measurable disease to be selected as a target on CT/MRI-
scan, according to RECIST criteria‡§
 ► Tumour visibility on CT
 ► If liver cirrhosis is present, it should be well compensated, 
with Child-Pugh grade A
 ► Age ≥18 years
 ► ECOG performance status 0–1
 ► Bilirubin ≤1.5 times normal value, AST/ALT ≤5 times ULN§
 ► Platelets ≥50×109/L, leucocytes >1.5×109/L, haemoglobin 
>6 mmol/L (9.67g/dL)§
 ► Written informed consent
 ► Willing and able to comply to the follow-up schedule
 ► Able to start SBRT within 12 weeks after completion of 
chemotherapy.
 ► Eligibility for resection
 ► Prior surgery or transplantation
 ► Multifocal tumour
 ► Tumour extension in stomach, colon, duodenum, pancreas 
or abdominal wall
 ► N2, (AJCC staging seventh edition), radiologically or 
pathologically suspect†
 ► Distant metastases
 ► Progression (local or distant) during or after chemotherapy
 ► Ascites
 ► Previous radiotherapy to the liver
 ► Current pregnancy
*If less cycles have been given, patients are still eligible for this study.
†Before chemotherapy.
‡After chemotherapy.
§Within 6 weeks prior to inclusion.
AJCC, American Joint Committee on Cancer;  ALT, alanine transaminase; AST, aspartate transaminase; CCA,  cholangiocarcinoma; ECOG-
PS, Eastern Cooperative Oncology Group performance status; FISH, fluorescence in situ hybridization; SBRT, stereotactic body radiation 
therapy.  
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constraints in the surrounding OAR (tables 3 and 4). This 
approach has already been tested with favourable outcome 
and limited biliary toxicity in a multicentre retrospec-
tive study for intrahepatic CCA.20 The same radiotherapy 
protocol (dose and fractionation) is currently being tested 
in a prospective phase III trial between chemotherapy and 
chemotherapy combined with radiotherapy in patients with 
unresectable intrahepatic CCA (NRG-GI001). To the best 
of our knowledge, this approach for perihilar CCA has not 
been published yet.
Marker implantation
A tumour-tracking technique (Synchrony-Cyberknife, 
Accuray, Sunnyvale, California, USA) will be applied for 
daily positioning and during dose delivery. Therefore, 
implantation of fiducials is compulsory. For perihilar CCA, 
Table 3 Organs at risk constraints
Organ at risk Hard constraints
Healthy liver ≥700 mL liver-GTV, 
dose <25.5 Gy26
If cirrhosis is present: NTCP 
liver-GTV ≤5%27 and >800 mL 
liver-GTV, dose <31.5 Gy28
Stomach Max point dose <57 Gy29
Volume receiving ≥41 Gy 
should be ≤5 cc
Duodenum
Small and large bowel (when 
needed combined in one 
structure)
Max point dose <57 Gy29
Volume receiving ≥41 Gy 
should be ≤5 cc
Oesophagus Max point dose ≤50.25 Gy30
Spinal cord Max point dose ≤33.8 Gy26
Kidney 2/3 right kidney <25.5 Gy26
Table 4 Organ at risk objectives 
Organ at risk Objectives
Central biliary tract Less than 0.5 cc ≥70 Gy
(NRG-GI001 - http://www.cancer.gov/
clinicaltrials)
VBED1040<37 cc and VBED1030<45 cc
31
Heart Max dose <57 Gy
(RTOG 1112 - http://www.cancer.gov/
clinicaltrials)
Gallbladder Max dose <86.7 Gy
(RTOG 1112- http://www.cancer.gov/
clinicaltrials)
Skin (external 
contour)
Less than 0.5 cc ≥50.25 Gy
(RTOG 1112 - http://www.cancer.gov/
clinicaltrials)
RTOG, Radiation Therapy Oncology Group. 
Figure 1 Study outline. SBRT, stereotactic body radiation therapy.
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fiducials should be implanted in the liver and not in the 
tumour to avoid the risk of tumour seeding. A distance of 
around 2.0 cm from the tumour edge is recommended. 
The procedure will be performed by an experienced inter-
ventional radiologist. International normalised ratio (INR) 
should be <2.0, and platelets should be ≥50×109/L. We will 
plan around 1 week (minimum of 5 and maximum of 10 
days) between the implantation of the fiducials and the treat-
ment preparation (planning CT). Patients should remain 
hospitalised during at least 2–3 hours after the implantation 
in order to detect and treat unexpected complications as 
soon as possible. In case of lymph node involvement, no 
fiducials will be implanted in the affected nodes.
Tumour delineation
The gross target volume (GTV) is defined in a contrast-en-
hanced CT acquired in expiration and in a hepatic venous 
phase. An arterial phase CT with bolus-tracking technique 
is also performed since valuable complementary informa-
tion from this phase could be valuable to better depict the 
tumour. The use of MRI to support the tumour delinea-
tion is recommended. In case that enlarged lymph nodes 
(N1) have to be considered as a target for SBRT, the venous 
phase of the planning CT in expiration will also be used 
for the delineation. No additional margin will be added 
around the GTV to generate the clinical target volume for 
both tumour and lymph nodes.
Margins
The information acquired from a 4DCT scan and from 
the inspiration/expiration CT will be used to establish the 
margin around the GTV to generate the planning target 
volume (PTV). This margin should ensure that despite 
geometrical uncertainties (ie, imaging artefacts in the plan-
ning CT scan due to respiratory tumour motion, interfrac-
tion motion of the tumour, uncertainty in the set-up, etc), 
the full GTV is irradiated with an adequate dose with a very 
high probability.
Planning protocol
Efforts should be made to deliver a BED >80.5 Gy to the 
tumour, since a multicentre retrospective study of intrahe-
patic CCA demonstrated a significant improvement in LC 
depending on the BED (3y 45% for BED <80.5 Gy vs 78% for 
BED >80.5 Gy).20 In case the tumour is located very close/
adjacent to OAR as the duodenum, stomach, oesophagus 
or bowel, it may be impossible to deliver such high doses to 
the periphery of most of the tumour, and therefore, lower 
doses at the periphery are allowed in these cases.
Any plan delivered to a patient should adhere to the 
imposed OAR hard constraints (table 3). Within these 
constraints, ideally the full PTV is irradiated with a dose 
of ≥67.5 Gy (15×4.5 Gy). Due to the hard constraints and 
the objectives for the OARs, this ideal PTV dose may not 
always be achievable. In that case, compromises in PTV dose 
delivery can be made. First of all, the PTV coverage may be 
reduced, that is, only 95% of the PTV may receive ≥67.5 Gy. 
Second, instead of delivering 67.5 Gy (15×4.5 Gy), a dose 
of 60 Gy (15×4 Gy), 52.5 Gy (15×3.5 Gy) or even 45 Gy 
(15×3 Gy) can be chosen. An effort should be made to 
deliver at least 60 Gy (BED >80.5 Gy) to a large portion of 
the PTV without violating OAR constraints.
Fractionation and daily imaging
The total dose is delivered in 15 fractions. Time between 
fractions should be 24 hours (in case of a weekend in 
between it will be 72 hours). Effort should be made to 
deliver the treatment without gaps.
In order to evaluate the relationship between tumour 
and OAR in this perihilar location, a CT scan before and 
after treatment in expiration phase will be performed in 
treatment position the first day and on days 3, 6, 9, 12 and 
15 during treatment. No intravenous contrast will be used.
Post-SBRT follow-up
Follow-up visits will be scheduled at 1, 3, 6, 9, 12, 18 and 24 
months after treatment. At every visit, an MRI or CT scan 
will be made to detect local or distant disease progression. 
Also, toxicity and performance score will be scored every 
visit. Patients will be asked to fill out QoL questionnaires 
(EuroQol EQ-5D-5L, EORTC QLQ-C30 and EORTC QLQ- 
BIL21) at most visits. For further detailed information, see 
table 5. If a patient is still alive after 2 years, follow-up will 
be continued by the medical oncologist according current 
clinical practice.
Ancillary study: evaluating cellular radiosensitivity in patient-
derived organoid models
We will grow organoids from tumour and bile duct cells 
collected by brush biopsies23 (Broutier et al tumour-de-
rived organoid cultures model primary human liver 
cancer in vitro, article in press). For this purpose, a 
second brush will be obtained during the same procedure 
while the first brush is taken (just directly after the first 
one) and only for patients where a brush biopsy is consid-
ered needed as part of the diagnostic work-up. We will 
set up assays to measure cell survival (clonogenic assays, 
H&E staining of organoids), apoptosis (terminal deoxy-
nucleotidyl transferase dUTP nick and labeling (TUNEL) 
staining), accumulation of DNA repair proteins on DNA 
double-strand breaks (gamma-H2AX, 53BP1 and RAD51 
foci) and repair of the DNA damage at various time points 
after irradiation (loss of these foci after 24–48 hours of 
incubation). In addition to the functional assays, organoid 
cultures are also ideal sources of tumour material, such as 
DNA for mutation analysis and RNA for gene expression 
studies.24
data analysis
This trial will be performed as a feasibility study and will 
focus on toxicity until 3 months after SBRT treatment. The 
number of patients with LT as defined before will be deter-
mined. If two or more patients have LT, the conclusion will 
be that the regimen is not feasible. Otherwise the conclu-
sion will be that the regimen warrants further research in 
this population.
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In addition, the analysis of toxicity will be done by tabu-
lation of the incidence of adverse events CTCAE grades 3 
and 4. Adverse events will be summarised by worst CTCAE 
grade. Demographics of the patients at study entry will be 
recorded, and presented as percentages in case of discrete 
variables, or by median and range in case of continuous 
variables. All patients with the baseline and at least one 
follow-up QoL questionnaire, separately for QLQ-C30, 
QLQ-BIL21 and EuroQoL-5D, will be included in the anal-
ysis. The repeated measures will be analysed using analysis 
of variance models. The Kaplan-Meier method will be used 
to estimate LC, progression-free survival and OS.
Patient and public involvement
While designing the study, our first priority was the patients’ 
well-being. Although we did not involve patients in the 
design of the trial, all information about the study is avail-
able on the website of the Dutch Hepato & Cholangio 
Carcinoma Group (www. dhcg. org). During the develop-
ment phase, the study was discussed several times within 
this multidisciplinary group. A final report of the trial will 
also be placed at the website for patient information. At any 
time, participants can be informed about study outcomes 
through the principal investigator.
EthICs And dIssEMInAtIon
The STRONG trial is registered on  ClincalTrials. gov (ID: 
NCT03307538). The results of this study will be published 
in an academic journal, and presented at national and 
international conferences.
dIsCussIon
The STRONG trial is designed to assess feasibility and 
toxicity of adding SBRT to standard chemotherapy in 
patients with inoperable perihilar CCA. Currently, only a 
few prospective studies are available on the use of SBRT for 
treating patients with CCA in the perihilar region. These 
studies report promising results for LC (≥72% at 2 years) 
and median OS (up to 35 months), with low toxicity rates. 
However, the exact treatment approach (combination with 
chemotherapy, chemotherapy scheme, timing, SBRT frac-
tionation) varied widely.13–21 The scarce available results 
suggest that the combination of chemotherapy and SBRT 
may improve disease control above SBRT alone.
We chose a more fractionated scheme than the other 
studies on SBRT for perihilar tumours because of the prox-
imity of OAR like duodenum and bile duct to the tumour. 
By using 15 fractions, instead of fewer, we hope to reach an 
acceptable coverage of the PTV with a BED of more than 
80.5 Gy, and at the same time respect the dose constraints 
for the OAR’s. Acceptable results have been published with 
this fractionating scheme for intrahepatic CCA.20
In this study, we will encounter some technical chal-
lenges and uncertainties. First of all is the assessment of the 
breathing motion of tumours located in the perihilar region. 
Since we use the Synchrony-Cyberknife system for tumour 
tracking, fiducial markers will have to be implanted close 
to the tumour. These markers will be placed in the liver in 
the proximity of the tumour and not in the tumour itself to 
avoid tumour seeding. Second, there is little known about 
the interfraction and intrafraction motion of OAR located 
in the vicinity of the perihilar region and the correlation 
with the tumour motion. If present, involved lymph nodes 
may be situated at a certain distance of the tumour. Again, 
motion assessment and correlation with tumour motion 
will be another point that should be addressed within this 
study. In order to measure variations in interfraction and 
intrafraction motion, a CT scan in expiration phase before 
Table 5 Schedule of events
Eligibility 
check
Written 
informed 
consent
Medical 
history Comorbidity
ECOG 
PS Laboratory* CT/MRI†
Adverse 
events‡ QOL
Survival and 
poststudy 
treatment
Standard treatment (chemotherapy) 1–8 courses. No progressive disease
  ≤6 weeks X X X X X X X X X
Experimental add on treatment (SBRT)
  +1 month X X X X X X
  +3 months X X X X X X
  +6 months X X X X X X
  +9 months X X X X X X
  +12 months X X X X X X
  +18 months X X X X X
  +24 months X X X X X X
*Laboratory assessments should include albumin, bilirubin, alkaline phosphatase, AST, ALT, gamma-glutamyl transferase (GGT), 
haemoglobin (Hb), leucocytes, platelets and CA-19.9. Notice that CA-19.9 should only be assessed during follow-up if indicated, that is, if 
elevated at baseline.
†Radiology report should include tumour measurement, tumour measurements should be performed according to RECIST criteria.
‡CTCAE V.4.03 should be applied for grading toxicity.
CTCAE, Common Toxicity Criteria for Adverse Events; QOL, quality of life; SBRT, stereotactic body radiation therapy. 
 o
n
 29 O
ctober 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020731 on 15 October 2018. Downloaded from 
8 Koedijk MS, et al. BMJ Open 2018;8:e020731. doi:10.1136/bmjopen-2017-020731
Open access 
and after treatment will be performed in treatment position 
the first day and on days 3, 6, 9, 12 and 15 during treatment.
Because of these technical uncertainties in combination 
with the experimental fractionation scheme for tumours 
located in the perihilar region, the first step is to complete 
this feasibility trial with just six patients. Since this small 
number results in limitations for interpreting results on 
disease control and QoL, our aim is to proceed to a large 
phase II trial if the treatment turns out to be feasible.
Author affiliations
1Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The 
Netherlands
2Department of Surgery, Erasmus MC University Medical Center, Rotterdam, The 
Netherlands
3Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The 
Netherlands
4Department of Gastroenterology and Hepatology, Erasmus MC University Medical 
Center, Rotterdam, The Netherlands
5Department of Molecular Genetics, Erasmus MC University Medical Centre, 
Rotterdam, The Netherlands
6Department of Haematology, Erasmus MC Cancer Institute, Rotterdam, The 
Netherlands
7Department of Radiology and Nuclear Medicine, Erasmus MC University Medical 
Center, Rotterdam, The Netherlands
Contributors All authors contributed to the design of the study protocol and 
approved the final manuscript. AMR and MSK: principal investigators, initiators of 
the trial. BJMH: medical physics aspects. BvdH: statistical design and data analysis. 
DCvG and LJWvdL: molecular genetics side study. FEJAW: radiological support. 
BGK: surgical aspects. FALME: systemic therapy advice. DS and J-WP: endoscopic 
and gastroenterological procedures.
Funding The authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not-for-profit sectors. 
Competing interests None declared.
Patient consent Obtained.
Ethics approval Ethics approval for the study was granted 31 August 2017 by 
the Medical Ethics Committee of Erasmus MC Rotterdam, the Netherlands (ID: NL 
60588.078.17). 
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
rEFErEnCEs
 1. Aitken KL, Hawkins MA. The role of radiotherapy and chemoradiation 
in the management of primary liver tumours. Clin Oncol 
2014;26:569–80.
 2. Shinohara ET, Mitra N, Guo M, et al. Radiotherapy is associated with 
improved survival in adjuvant and palliative treatment of extrahepatic 
cholangiocarcinomas. Int J Radiat Oncol Biol Phys 2009;74:1191–8.
 3. Weiss MJ, Cosgrove D, Herman JM, et al. Multimodal treatment 
strategies for advanced hilar cholangiocarcinoma. Langenbecks Arch 
Surg 2014;399:679–92.
 4. Mansour JC, Aloia TA, Crane CH, et al. Hilar cholangiocarcinoma: 
expert consensus statement. HPB 2015;17:691–9.
 5. Blechacz B. Cholangiocarcinoma: Current Knowledge and New 
Developments. Gut Liver 2017;11:13–26.
 6. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus 
gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273–81.
 7. Eckmann KR, Patel DK, Landgraf A, et al. Chemotherapy 
outcomes for the treatment of unresectable intrahepatic and hilar 
cholangiocarcinoma: a retrospective analysis. Gastrointest Cancer 
Res 2011;4(5-6):155–60.
 8. Coelen RJS, Vogel JA, Vroomen L, et al. Ablation with 
irreversible electroporation in patients with advanced perihilar 
cholangiocarcinoma (ALPACA): a multicentre phase I/II feasibility 
study protocol. BMJ Open 2017;7:e015810.
 9. Melenhorst MC, Scheffer HJ, Vroomen LG, et al. Percutaneous 
Irreversible Electroporation of Unresectable Hilar 
Cholangiocarcinoma (Klatskin Tumor): A Case Report. Cardiovasc 
Intervent Radiol 2016;39:117–21.
 10. Wu TT, Li WM, Li HC, et al. Percutaneous intraductal radiofrequency 
ablation for extrahepatic distal cholangiocarcinoma: A method for 
prolonging stent patency and achieving better functional status and 
quality of life. Cardiovasc Intervent Radiol 2017;40:260–9.
 11. Wagner A, Denzer UW, Neureiter D, et al. Temoporfin improves 
efficacy of photodynamic therapy in advanced biliary tract 
carcinoma: A multicenter prospective phase II study. Hepatology 
2015;62:1456–65.
 12. Mattiucci GC, Autorino R, Tringali A, et al. A Phase I study of high-
dose-rate intraluminal brachytherapy as palliative treatment in 
extrahepatic biliary tract cancer. Brachytherapy 2015;14:401–4.
 13. Mahadevan A, Dagoglu N, Mancias J, et al. Stereotactic Body 
Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma. 
J Cancer 2015;6:1099–104.
 14. Kopek N, Holt MI, Hansen AT, et al. Stereotactic body radiotherapy for 
unresectable cholangiocarcinoma. Radiother Oncol 2010;94:47–52.
 15. Tse RV, Hawkins M, Lockwood G, et al. Phase I study of 
individualized stereotactic body radiotherapy for hepatocellular 
carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 
2008;26:657–64.
 16. Polistina FA, Guglielmi R, Baiocchi C, et al. Chemoradiation 
treatment with gemcitabine plus stereotactic body radiotherapy 
for unresectable, non-metastatic, locally advanced hilar 
cholangiocarcinoma. Results of a five year experience. Radiother 
Oncol 2011;99:120–3.
 17. Barney BM, Olivier KR, Miller RC, et al. Clinical outcomes and 
toxicity using stereotactic body radiotherapy (SBRT) for advanced 
cholangiocarcinoma. Radiat Oncol 2012;7:67.
 18. Momm F, Schubert E, Henne K, et al. Stereotactic fractionated 
radiotherapy for Klatskin tumours. Radiother Oncol 2010;95:99–102.
 19. Jung DH, Kim MS, Cho CK, et al. Outcomes of stereotactic 
body radiotherapy for unresectable primary or recurrent 
cholangiocarcinoma. Radiat Oncol J 2014;32:163–9.
 20. Tao R, Krishnan S, Bhosale PR, et al. Ablative radiotherapy doses 
lead to a substantial prolongation of survival in patients with 
inoperable intrahepatic cholangiocarcinoma: a retrospective dose 
response analysis. J Clin Oncol 2016;34:219–26.
 21. Sandler KA, Veruttipong D, Agopian VG, et al. Stereotactic body 
radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic 
cholangiocarcinoma. Adv Radiat Oncol 2016;1:237–43.
 22. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response 
evaluation criteria in solid tumours: revised RECIST guideline (version 
1.1). Eur J Cancer 2009;45:228–47.
 23. Huch M, Gehart H, van Boxtel R, et al. Long-term culture of 
genome-stable bipotent stem cells from adult human liver. Cell 
2015;160:299–312.
 24. Blokzijl F, de Ligt J, Jager M, et al. Tissue-specific mutation 
accumulation in human adult stem cells during life. Nature 
2016;538:260–4.
 25. Welling TH, Feng M, Wan S, et al. Neoadjuvant stereotactic body 
radiation therapy, capecitabine, and liver transplantation for 
unresectable hilar cholangiocarcinoma. Liver Transpl 2014;20:81–8.
 26. Schefter TE, Kavanagh BD, Timmerman RD, et al. A phase I trial of 
stereotactic body radiation therapy (SBRT) for liver metastases. Int J 
Radiat Oncol Biol Phys 2005;62:1371–8.
 27. Dawson LA, Eccles C, Craig T. Individualized image guided iso-NTCP 
based liver cancer SBRT. Acta Oncol 2006;45:856–64.
 28. Son SH, Choi BO, Ryu MR, et al. Stereotactic body radiotherapy 
for patients with unresectable primary hepatocellular carcinoma: 
dose-volumetric parameters predicting the hepatic complication. Int 
J Radiat Oncol Biol Phys 2010;78:1073–80.
 29. Kavanagh BD, Pan CC, Dawson LA, et al. Radiation dose-volume 
effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys 
2010;76(3 Suppl):S101–7.
 30. Kong FM, Ritter T, Quint DJ, et al. Consideration of dose limits 
for organs at risk of thoracic radiotherapy: atlas for lung, proximal 
bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. Int 
J Radiat Oncol Biol Phys 2011;81:1442–57.
 31. Toesca DA, Osmundson EC, Eyben RV, et al. Central liver toxicity 
after SBRT: An expanded analysis and predictive nomogram. 
Radiother Oncol 2017;122:130–6.
 o
n
 29 O
ctober 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020731 on 15 October 2018. Downloaded from 
